SCHEMBL15946346

SCHEMBL15946346

Cc1ccc2nc(-c3ccc(NC(=O)c4ccc(NC(=O)c5ccc(C(F)(F)F)cc5)cc4)cc3)sc2c1S(=O)(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.58
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
CYP3A4 P08684 1/20 0.58
GAA P10253 1/20 0.58
HPGD P15428 1/20 0.58
NT5E P21589 1/20 0.58
CASP1 P29466 1/20 0.58
RECQL P46063 1/20 0.58
CASP7 P55210 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
TRPV1 Q8NER1 4/20 0.48
MCHR1 Q99705 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15940381 0.95 TP53 (0.52) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768710 0.89 TP53 (0.61) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768738 0.89 ALDH1A1 (0.52) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768734 0.88 ALDH1A1 (0.76) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768745 0.87 ALDH1A1 (0.54) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768703 0.86 TP53 (0.58) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768700 0.86 ALDH1A1 (0.53) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768602 0.86 TP53 (0.49) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL15946365 0.86 ALDH1A1 (0.49) TP53ALDH1A1GLACYP3A4GAA
SCHEMBL14768718 0.86 ALDH1A1 (0.48) TP53ALDH1A1GLACYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9464064-B2 HCV helicase inhibitors and methods of use thereof UNIVERSITY OF KANSAS (US) 2016-10-11 US disclosed
US-9464064-B2 HCV helicase inhibitors and methods of use thereof UNIVERSITY OF KANSAS (US) 2016-10-11 US disclosed
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof UWM RESEARCH FOUNDATION, INC. (US) 2014-08-14 US disclosed
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof UWM RESEARCH FOUNDATION, INC. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof DHX15, DDX5, DHX35 TP53 446/4885ALDH1A1 1138/4885GLA 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.